-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK wins FDA accelerated approval for Nelkarmi in previously treated ALK-positive lung cancer

PUBT·11/17/2026 19:10:48
Listen to the news
GSK wins FDA accelerated approval for Nelkarmi in previously treated ALK-positive lung cancer
  • FDA grants accelerated approval to GSK’s Nelkarmi for adults with previously treated advanced ALK-positive non-small cell lung cancer.
  • The decision comes ahead of the agency’s original November 27, 2026, target action date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.